Friday, 4 September 2015

Peptide Therapeutics Market Size: product price, profit, capacity, production, Market growth rate etc.

Industry Insights
Peptide therapeutics market is expected to grow over the forecast period owing to the increasing prevalence of cancer and other various metabolic diseases. The other growth drivers of this market are introduction of technological advancements such as hybrid method of synthesis of peptides, lifestyle induced diseases such as obesity & diabetes, sophisticated healthcare infrastructure, increasing population and awareness. Peptides are referred as amide bonds which are linked with small chains of amino acid monomers. Peptides differ from protein on the basis of size. The presence of amino acids in peptides is less than 55 molecules.

 Peptides crunch themselves to some imitate such as receptor ligands and specific cell surface receptors. As peptides act on cell membrane, so it helps peptides in treating various diseases. As the market has a huge potential, thus various biotechnology and pharmaceutical industries are developing new peptides that can be used for various purposes. So these companies are actively investing in high R&D activities. Globally, cancer has been a foremost cause of death.

Technology Insight

Peptide therapeutics market is segmented on the basis of technology into HPPS, LPPS and SPPS. Among these SPPS technology held the largest market share in 2013 due to user friendliness and cost effective. In recent years HPSS technology has generated huge momentum and it is expected to be fastest growing technology over the forecast period.

Application Insights

Peptide therapeutics market is segmented on the basis of application into metabolic, cancer, CNS and CVS. In 2013, Peptide therapeutics had occupied most of the market share as it is used for treatment of cancer. Growing incidences of cancer and awareness is expected to drive the market over the forecast period.

Segment (Route of Administration) Insight

Peptide therapeutics market is segmented on the basis route of administration into oral, parenteral, mucosal and pulmonary. Among these parenteral routes held the largest market share in 2013, as it is used for a long time. Over the upcoming five years higher comfort level of patients is expected to drive the parenteral route.

Request a Sample copy of This Report @

Product Insight
Peptide therapeutics market is segmented on the basis product types into generic and innovative. Among these, innovative peptides held the largest market share in 2013, as it is cost effective as compared to generic peptides. With the help of technological advancement it is expected to grow over the forecast period.

Regional Insights
Geographically, the Peptide therapeutics market is studied by segmenting the market into North America, Europe, Asia Pacific and RoW. North America is dominating the whole market due to high per capita healthcare expenditure, sophisticated healthcare infrastructure, rising disposable income, various government or NGO’s initiatives and increasing geriatric population. Asia Pacific is expected to witness lucrative growth rate over the forecast period due to increasing population, government initiatives and growing economies.

Competitive Insights
The major market players in the Peptide therapeutics market are Bristol-Myers Squibb (BMS), Amylin Pharmaceuticals LLC, Bachem Holding AG, Roche, Amgen Inc., Peptisyntha, Ipsen, Eli Lilly and Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Merck & Co., Lonza Inc., Novartis AG, GlaxoSmithKline (GSK), PolyPeptide Group, Novo-Nordisk A/S, Pfizer Inc., Sanofi, and Teva Pharmaceuticals.

Table of Contents

Chapter 1 Executive Summary
1.1 Peptide Therapeutics – Industry Summary & Critical Success Factors (CSFs)

Chapter 2 Peptide Therapeutics Industry Outlook
2.1 Market Segmentation
2.2 Market Size and Growth Prospects
2.3 Peptide Therapeutics Value Chain Analysis
2.4 Peptide Therapeutics Market Dynamics
2.5 Key Opportunities Prioritized
2.6 Industry Analysis - Porter's
2.7 Peptide Therapeutics - Company Market Share Analysis
2.8 Peptide Therapeutics - PESTEL Analysis

Chapter 3 Peptide Therapeutics Technology Outlook
3.1 Solid Phase Peptide Synthesis (SPPS)
3.2 Liquid Phase Peptide Synthesis (LPPS)
3.3 Hybrid Phase Peptide Synthesis (HPSS)

Chapter 4 Peptide Therapeutics Application Outlook
4.1 Cancer
4.2 Metabolic
4.3 Cardiovascular
4.4 Dermatology
4.5 Anti-infection
4.6 Gastro Intestinal
4.8 Respiratory
4.9 Pain
4.10 Others

Browse Healthcare IT Market Research Related Reports @

Chapter 5 Peptide Therapeutics Route Outlook
5.1 Parenteral Route
5.2 Oral Route
5.3 Pulmonary Route
5.4 Mucosal Route
5.5 Other Routes (Intradermal & Nasal)

Chapter 6 Peptide Therapeutics Product Outlook
6.1 Innovative
6.2 Generic

Chapter 7 Peptide Therapeutics Regional Outlook
7.1 North America
7.2 Europe
7.3 Asia Pacific
7.4 RoW

Chapter 8 Competitive Landscape
8.1 Amgen Inc.
8.2 Amylin Pharmaceuticals LLC- Bristol- Myers Squibb (BMS)
8.3 AstraZeneca PLC
8.4 Bachem Holding AG
8.5 Eli Lilly and Company
8.6 GlaxoSmithKline (GSK)
8.7 Ipsen
8.8 Lonza Inc.
8.9 Merck & Co.
8.10 Novartis AG
8.11 Novo- Nordisk A/S
8.12 Peptisyntha
8.13 PolyPeptide Group.
8.14 Pfizer Inc.
8.15 Roche

Chapter 9 Methodology & Scope
9.1 Research Methodology
9.2 Research Scope & Assumptions
9.3 List of Data Sources

About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Information:

Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075

No comments:

Post a Comment